microbiome

Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Takeda-partnered Finch Therapeutics grabs $36M and looks to leapfrog the pack in microbiome R&D
Endpoints
Takeda
Finch Therapeutics
microbiome
R&D
Flag link:
Pharma moves beyond Seres hangover in microbiome space
Pharma moves beyond Seres hangover in microbiome space
Biopharma Dive
Seres Therapeutics
microbiome
Flag link:
Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018
Trump v. Drug Makers? And 6 More Burning Biopharma Questions for 2018
Xconomy
Donald Trump
pharma industry
gene therapy
DNA testing
opioid crisis
drug development
digital healthcare
microbiome
Flag link:
Not your mom’s probiotic: Google-backed Evelo teams up with Mayo Clinic on microbiome drugs
Not your mom’s probiotic: Google-backed Evelo teams up with Mayo Clinic on microbiome drugs
Endpoints
Google
Evelo
Mayo Clinic
microbiome
Flag link:
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Takeda partner Finch joins forces with Crestovo, leaping into a late-stage microbiome study
Endpoints
Takeda
Finch Therapeutics
Crestovo
C. difficile
microbiome
CP101
Flag link:
Evelo Bio Raises $50M Round to Bring Microbiome Drugs Into Trials
Evelo Bio Raises $50M Round to Bring Microbiome Drugs Into Trials
Xconomy
Evelo Biosciences
microbiome
Flag link:
FDA digests Ritter's mid-stage microbiome data
FDA digests Ritter's mid-stage microbiome data
BioPharma Dive
FDA
Ritter
microbiome
RP-G28
lactose intolerance
clinical trials
Flag link:
Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study
Seres doubles down on a microbiome do-over as the FDA clears a make-or-break study
Endpoints
Seres Therapeutics
microbiome
FDA
clinical trials
SER-109
Flag link:
Microbiome work reignites after Seres' initial flame-out
Microbiome work reignites after Seres' initial flame-out
BioPharma Dive
Seres Therapeutics
microbiome
Flag link:
Seres Therapeutics To Conduct First Clinical Trial Of Synthetic Microbiome Drug
Seres Therapeutics To Conduct First Clinical Trial Of Synthetic Microbiome Drug
Xtalks
Seres Therapeutics
clinical trials
SER-262
microbiome
Clostridium Difficile
Flag link:
Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome
Pfizer, Roche Embrace The Microbiome, Leading $43M Bet On Second Genome
Forbes
Pfizer
Roche
microbiome
Second Genome
Flag link:
Which Biotechnologies Were Hyped (And Which Went Out Of Favor) In 2015
Which Biotechnologies Were Hyped (And Which Went Out Of Favor) In 2015
Forbes
biotech
CRISPR
microbiome
genomic wellness
stem cells
molecular diagnostics
Flag link:
Novartis backs $176M microbiome biotech fund
Novartis backs $176M microbiome biotech fund
Fierce Biotech
Novartis
microbiome
Seventure Partners
Flag link:
IPO Preview: Seres Therapeutics
IPO Preview: Seres Therapeutics
Seeking Alpha
IPOs
Seres Therapeutics
microbiome
Flag link:
Seres guts out a $134M IPO to fuel microbiome R&D
Seres guts out a $134M IPO to fuel microbiome R&D
Fierce Biotech
Seres
microbiome
IPOs
R&D
Flag link:
J&J in deal to develop microbiome drug for bowel diseases
J&J in deal to develop microbiome drug for bowel diseases
Yahoo/Reuters
JNJ
microbiome
inflammatory bowel disease
Vedanta Biosciences
Flag link:
Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal
Pfizer jumps on the microbiome bandwagon with expansive Second Genome deal
Fierce Biotech
Second Genome
Pfizer
obesity
microbiome
Flag link:
Johnson & Johnson's Gut Feeling About the Future of Medicine
Johnson & Johnson's Gut Feeling About the Future of Medicine
Motley Fool
JNJ
microbiome
Second Genome
Flag link: